Titlebook: Induction Chemotherapy; Systemic and Locoreg Karl Reinhard Aigner,Frederick O. Stephens Book 2016Latest edition Springer-Verlag Berlin Heid

改進

Miriam R. Habib,David L. Morrisr object attributes as a consequence of access have not been systematically studied. In this paper we motivate the need for usage control, define a family of ABC models as a core model for usage control and show how it encompasses traditional access control, such as mandatory, discretionary and role

FLIP

BUCK

Induction Chemotherapy for Breast Cancer,r patients undergoing induction chemotherapy is the combination of an anthracycline (doxorubicin or epirubicin) + cyclophosphamide ± 5-FU followed by taxanes (weekly paclitaxel or docetaxel). For patients who cannot receive anthracycline therapy, docetaxel in combination with cyclophosphamide is a g

CANON

滲透

惡臭

Induction Bidirectional Chemotherapy for Gastric Cancer with Peritoneal Dissemination, % with a median survival of 20.4 months. Gastrectomy with peritonectomy to eliminate all visible evidence of disease after a response to induction bidirectional chemotherapy should be considered in patients with primary gastric cancer and carcinomatosis.

neologism

Gastric Cancer,al surgery..In cases of more advanced disease, induction chemotherapy can render inoperable tumors resectable. Other advantages of induction therapy include the ability to obtain information about tumor response, which can be used to study the biologic effects of chemotherapy and assess long-term di

nugatory

Nutrient

Induction Chemotherapy for Hepatocellular Carcinoma,ional chemotherapy of the liver. The phase I study of PIHP for advanced HCC showed favorable treatment results. Currently, phase II and III trials for HCC are taking place in the United States as a multicenter study..During the last decade, many molecular targeted agents have been researched in clin

Cupping